The Asia-Pacific next-generation diagnostics sector's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus on breakthrough innovation, diagnostic services must be revamped to meet reduced price points for low-resource settings.
• How do product developments and business models combined with a focus on care delivery contribute to growth?
• What strategies can be employed to harness the platform-as-a-service business model in this industry?
• What are the potential emerging opportunities, and how can they be capitalized on?
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled industry intelligence, technology advancements, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
